Month: March 2022

Fourth-Quarter Revenue of $7.2 million; Full-Year Revenue of $26.0 million Advanced OLED Manufacturing Equipment to be Added to Production Through 2022 Strong Backlog of Open Orders of $13.8 million increased 26% from the end of 2020 HOPEWELL JUNCTION, N.Y., March 10, 2022 (GLOBE NEWSWIRE) — eMagin Corporation, or the “Company,” (NYSE American: EMAN), a leader in the development, design and manufacture of Active Matrix OLED microdisplays for high-resolution, AR/VR and other near-eye imaging products, today announced results for its fourth quarter and full-year 2021. “Thanks to our skilled workforce and their dedication to our mission of producing the world’s leading OLED microdisplays, 2021 was a year of great technical achievement for eMagin,” said eMagin CEO Andrew G. Sculley. “We ended the year with strong shipments of displays...

Generated revenue of $8.2 million for fiscal year 2021, growing 48% year over year, and gross profit of $6.6 million for fiscal year 2021, growing 62% year over year Delivered commercial availability of 80-Qubit Aspen-M System on Rigetti Quantum Cloud Services (QCS) and to end-users of Amazon Braket Established new collaborations with renowned public and private sector players, such as Ampere Computing, Nasdaq, Deloitte, DARPA, and the DOE, to advance key quantum computing applications with strong use case potential Announced collaboration with Microsoft to provide Rigetti quantum computers over the cloud to Microsoft’s Azure Quantum Service usersBERKELEY, Calif., March 10, 2022 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in hybrid quantum-classical computing, recently announced...

Increased dividend to $0.55 per share of common stock for Q1 2022, up 10% from prior quarterIncreased total commitments to $419.2 million as of December 31, 2021, up 288% from end of 2020Company to host a conference call at 10:00 am (Eastern Time) on Thursday, March 10, 2022 WEST PALM BEACH, Fla., March 10, 2022 (GLOBE NEWSWIRE) — AFC Gamma Inc. (NASDAQ:AFCG) (“AFCG” or “AFC Gamma”) today announced its results for the fourth quarter and year-ended December 31, 2021. Full Year 2021 HighlightsNet income of $21.0 million in 2021, or $1.57 per basic weighted average share of common stock Distributable earnings of $24.7 million in 2021, or $1.85 per basic weighted average share of common stock Book value per common share of $16.61 as of December 31, 2021, compared to $14.83 at the end of 2020 Closed $341.3 million of new commitments...

*Board Declares Cash Dividend YOQNEAM, Israel, March 10, 2022 (GLOBE NEWSWIRE) — MIND C.T.I. LTD. – (NasdaqGM: MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product based solutions for service providers, unified communications analytics and call accounting solutions for enterprises as well as enterprise messaging solutions, today announced results for its fourth quarter of 2021 and its full year ended December 31, 2021. The following will summarize our business in the fourth quarter of 2021 and provide a more detailed review of the financial results for the quarter and for the full year. Full financial results can be found in the Company News section of our website at http://www.mindcti.com/company/news/ and in our Form 6-K. Financial Highlights of Q4 2021Revenues of $6.0 million,...

Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, with Multiple Clinical and Regulatory Milestones Expected in 2022 NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter and full year ended December 31, 2021. “We remain committed to bringing new treatments to patients in areas of high unmet need,” said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. “With three ongoing Phase 3 studies across Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency and Diabetic Cardiomyopathy, we are advancing treatments forward, and expect multiple catalysts...

~ 2021 Revenue Increase of 50.8% Year-Over-Year to $549 Million ~ ~ 2021 Billings Increase of 33.0% Year-Over-Year to $730 Million ~ ~ 2021 Adjusted CFFO Increase of 46.8% Year-Over-Year to $197 Million ~ ~ Paid Subscribers Grew 13% Year-Over-Year to 972 Thousand ~ BALTIMORE, Md., March 10, 2022 (GLOBE NEWSWIRE) — MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for the fourth quarter and year ended December 31, 2021.Full Year 2021 and Fourth Quarter 2021 Key Performance Highlights(Unaudited)   4Q 2021   4Q 2020   FY 2021   FY 2020Total Subscribers (in thousands)             14,671     10,386          Paid Subscribers...

– Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 – – Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Planned in Mid-2022 – WALTHAM, Mass., March 10, 2022 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2021 and recent business highlights. “In 2021 we made significant achievements throughout the business. We generated platform-validating preclinical data across our programs, including demonstrating sustained knockdown of toxic nuclear DMPK RNA and correction of splicing in DM1 and...

First Quarter Fiscal 2022 Financial Highlights(All comparisons are year-over-year unless otherwise noted)Revenues of $31.8 million compared to $14.9 million Gross loss of ($2.9) million compared to $(3.6) million Loss from operations of $(44.8) million compared to $(14.4) million Results in the first quarter of fiscal 2022 were negatively impacted by a non-recurring expense of $24 million, or approximately $0.07 per share, related to payment of legal fees to our outside counsel in connection with settlement of the POSCO Energy dispute Backlog of $1.31 billion as of January 31, 2022, compared to $1.27 billion as January 31, 2021DANBURY, Conn., March 10, 2022 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) — a global leader in decarbonizing power and producing hydrogen through our proprietary, state-of-the-art fuel...

Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) — Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today provided an update on recent corporate developments and reported financial results for the full year ended December 31, 2021. “Graybug made important progress in advancing its retina (GB-102) and glaucoma (GB-401) programs in 2021. We developed a new enhanced formulation of GB-102 that capitalizes on the duration demonstrated by our Phase 2b ALTISSIMO trial, where half of patients were controlled for six months after a single intravitreal (IVT) injection,” said Frederic Guerard, PharmD, Chief Executive Officer of Graybug Vision. “We are in...